N=240 patients had available data and 177 remained on cenobamate (73.8% retention). 38 patients received concomitant clobazam at baseline; mean clobazam dose in ongoing cenobamate patients (n=30) decreased from 38.0 mg to 12.7 mg (initial to last dose) and 8/30 patients (26.7%) discontinued clobazam. In n=8 patients who discontinued cenobamate, clobazam dose was decreased less (35.6 mg to 24.4 mg). Among ongoing cenobamate patients who had clobazam dose decreases (n=25), the dose reductions occurred at mean visit 7.6 (~Week 10) and mean cenobamate dose at time of clobazam dose adjustment was 135.0 mg. Clobazam doses were decreased most often due to AEs (eg, tiredness/fatigue, sleepiness/drowsiness, slurred speech). 60/177 cenobamate patients (33.9%) were seizure-free ≥12 months and 6/60 (10.0%) were on concomitant clobazam, which is somewhat less than the percentage on concomitant clobazam of all patients (15.8%), those continuing cenobamate (16.9%), or those who discontinued cenobamate (12.7%). In 7 patients who discontinued clobazam, seizures reoccurred/worsened, and clobazam was resumed at lower doses (2.5-10 mg/day vs prior mean 32.9 mg/day) to improve seizure control.